Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 0%
Hold 63%
Sell 25%
Strong Sell 0%

Bulls say

RxSight is a commercial-stage medical technology company with a positive outlook due to its collaboration with ALC for light adjustable versions of certain ALC presbyopia correcting IOLs, which will provide up to $200 million in development and regulatory milestone payments and a potential 30% royalty on future sales. Additionally, the company's revenue beat consensus in 2Q26 and management reiterated its 2026 revenue guidance, giving confidence in potential growth. However, there are risks to consider, such as limited adoption and potential competition in the IOL market. Based on these factors, a Buy rating is maintained with a 12-month price target of $11-13.

Bears say

RxSight is facing several risks due to its limited adoption of an incremental capital equipment, disappointing commercial execution, increased competition in the intraocular lens market, and the potential for a dilutive financing round. Despite management's reassurance and recent revenue beat, the company's future success is heavily reliant on a steady recovery and re-engagement initiatives. Additionally, the company's high valuation multiples make it vulnerable to any potential setbacks, with a worst-case scenario of a $7 per share price estimate based on an EV/sales multiple of 0.5x the 2027 sales estimate.

RxSight (RXST) has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 0% recommend Buy, 63% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 8 analysts, RxSight (RXST) has a Hold consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.